{
  "id": "Ex058",
  "type": "Example",
  "informationId": {
    "id": "CG-EX:CritAssess334",
    "type": "CriterionAssessment",
    "criterion": {
      "id": "Crit322",
      "type": "Criterion",
      "description": "Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing",
      "comments": "\nThis will all depend on what is “established”, which could end up being defined by the different clinical domain working groups.\n",
      "defaultStrength": {
        "id": "SEPIO:0000328",
        "label": "Benign Strong"
      },
      "label": "BS3"
    },
    "variant": {
      "id": "CAR:CA501231",
      "type": "CanonicalAllele",
      "preferredCtxAllele": {
        "id": "CG-EX:CtxAll093",
        "type": "ContextualAllele",
        "relatedCanonicalAllele": "CAR:CA501231",
        "alleleName": "NM_152594.2(SPRED1): c.587C>T"
      }
    },
    "outcome": {
      "id": "SEPIO:0000223",
      "label": "Met"
    },
    "evidenceLine": [
      {
        "id": "CG-EX:EvLn077",
        "type": "EvidenceLine",
        "evidenceItem": [
          {
            "id": "CG-EX:Func194",
            "type": "AlleleFunctionalImpact",
            "resultDescription": "Unchanged from reference",
            "assayType": {
              "id": "AFAMID080",
              "label": "Elk1 pohsphorylation via luciferase assay"
            },
            "contextualAllele": {
              "id": "CG-EX:CtxAll093",
              "type": "ContextualAllele",
              "relatedCanonicalAllele": "CAR:CA501231",
              "alleleName": "NM_152594.2(SPRED1): c.587C>T"
            },
            "gene": {
              "id": "HGNC:20249",
              "label": "SPRED1"
            }
          }
        ]
      },
      {
        "id": "CG-EX:EvLn078",
        "type": "EvidenceLine",
        "evidenceItem": [
          {
            "id": "CG-EX:Func195",
            "type": "AlleleFunctionalImpact",
            "resultDescription": "localized to apical membrane",
            "assayType": {
              "id": "AFAMID080",
              "label": "Elk1 pohsphorylation via luciferase assay"
            },
            "contextualAllele": {
              "id": "CG-EX:CtxAll093",
              "type": "ContextualAllele",
              "relatedCanonicalAllele": "CAR:CA501231",
              "alleleName": "NM_152594.2(SPRED1): c.587C>T"
            },
            "gene": {
              "id": "HGNC:20249",
              "label": "SPRED1"
            }
          }
        ]
      }
    ],
    "contribution": [
      {
        "type": "Contribution",
        "agent": {
          "id": "CG-EX:Agent007",
          "type": "Agent",
          "label": "Stefan DiMarino"
        },
        "contributionDate": "9/5/16 9:31 AM",
        "contributionRole": {
          "id": "SEPIO:0000154",
          "label": "assessor role"
        }
      }
    ]
  },
  "index": 2,
  "author": "Marina DiStefano",
  "description": "Variant: NM_152594.2(SPRED1): c.587C>T (p.Thr196Ile)\n\nVariants in SPRED1 are associated with café au lait macules (CALMs), axillary freckling, and macrocephaly. Research has demonstrated that the protein is phosphorylated and inhibits differentiation in neurons by inhibiting Map Kinase.  1) A construct with the variant was transfected into PC12 cells and they were treated with nerve growth factor to stimulated neurite outgrowth. The variant did not reduce or alter neurite outgrowth. 2) Elk1 phosphorylation, a downstream readout of Map kinase activation, was also measured by a luciferase assay and found to be unchanged. The PMID for this is: 19920235.",
  "@context": "http://datamodel.clinicalgenome.org/interpretation/json/context"
}
